Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P41 vs Prolia in Postmenopausal Osteoporosis
NCT04757376Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of denosumab-nxxp in postmenopausal osteoporosis (2 arms), sponsored by Celltrion. Primary endpoint: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Week 52. Started Jun 2021; status: completed.
02
Drugs
denosumab-nxxp
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04757376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757376.